Biocon launches Yesafili biosimilar to Regeneron’s Eylea in US
REGN•Biocon launches Yesafili in the U.S.
Biocon Biologics launched Yesafili in the U.S., targeting a high-volume retinal disease market with an interchangeable biosimilar to Eylea 2 mg.
Interchangeability supports pharmacy-level substitution under state laws, strengthening pricing leverage with payers and accelerating uptake versus non-interchangeable rivals.
The launch positions the group to compete for share in a U.S. aflibercept market that generated about $5.89 billion of sales in 2023.
The move expands Biocon’s ophthalmology footprint, adding a new growth driver to its global biosimilars portfolio.
